Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Purpose: We tested the hypotheses that Src tyrosine kinase overactivity represents a chemoresistance mechanism and that Src inhibition may enhance gemcitabine cytotoxicity in pancreatic adenocarcinoma cells. Experimental Design: Pancreatic adenocarcinoma cells PANC1, MiaPaCa2, Capan2, BxPC3, and PANC1GemRes, a stably gemcitabine-resistant subline of PANC1, were exposed to combinations of gemcitabine and Src tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). Src expression, phosphorylation (Tyr-416), and activity were analyzed by immunoblotting and in vitro kinase assay. Expression of the M2 subunit of ribonucleotide reductase (RRM2), a putative chemoresistance enzyme, was quantified by Northern and Western blot. Cellular proliferation was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was characterized by YO-PRO-1/propidium iodide staining, fluorometric caspase profiling, and caspase inhibition (Z-Val-Ala-Asp-fluoromethyl ketone). The effects of constitutively active and dominant negative Src were determined. The therapeutic efficacy of PP2 in combination with gemcitabine was tested in nude mice orthotopically xenografted with PANC1GemRes. Results: Greater gemcitabine resistance was associated with higher Src phosphorylation and activity, both of which were higher in PANC1GemRes, relative to PANC1; total Src levels were alike. PANC1GemRes overexpressed RRM2. PP2 enhanced inherent gemcitabine chemosensitivity and attenuated gemcitabine resistance in PANC1GemRes. Constitutively active Src increased gemcitabine chemoresistance; dominant negative Src impaired gemcitabine chemoresistance. PP2 augmented gemcitabine-induced caspase-mediated apoptosis, suppressed RRM2 expression, and decreased activity of the RRM2-regulating transcription factor E2F1 in PANC1GemRes. PP2 and gemcitabine in combination substantially decreased tumor growth and inhibited metastasis in vivo. Conclusions: Increased Src tyrosine kinase activity represents a potential chemoresistance mechanism and a promising therapeutic target warranting further investigation in gemcitabine-resistant pancreatic adenocarcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, evidence from preclinical studies in sarcoma and ovarian cancer cell lines suggests that activation of Src reduces sensitivity to various chemotherapeutic drugs, including platinum agents, and that this resistance can be reversed by pharmacological inhibition [19, 20][21–23][24].”
From Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src (2016) · cites this paper as [22]
Citations
Cites
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481 · cited 1×
“Activated Akt directly phosphorylates initiator caspase 9, preventing its activation (46).”
BackgroundThe Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219 · cited 1×
“This effect would be of benefit in pancreatic tumors, which are by nature relatively avascular (45) and may receive subtherapeutic levels of cytotoxic agents.”
BackgroundDiscovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939 · cited 3×
“inhibit other intracellular kinases (14).”
BackgroundMethodInfluentialMechanisms and consequences of activation of protein kinase B/Akt
Downward, J. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80149-x · Cited by 1,303 · cited 3×
“activating phosphorylation of residues including Ser-473 at the COOH terminus (17, 18).”
BackgroundMethodExpression of transcription factor E2F1 induces quiescent cells to enter S phase
Johnson, D. G., Schwarz, J. K., Cress, W. D., & Nevins, J. R. (1993) · Nature · doi:10.1038/365349a0 · Cited by 943
DeGregori, J., Kowalik, T., & Nevins, J. R. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4215 · Cited by 919 · cited 12×
“Exposing PANC1GemRes to 1 M gemcitabine for 48 h had minimal effect on E2F1 activity in PANC1GemRes nuclear extract.”
BackgroundInfluentialRole of Src expression and activation in human cancer
Irby, R. B., & Yeatman, T. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203912 · Cited by 857 · cited 1×
“(41), including pancreatic adenocarcinoma (9), and overexpres-”
Mechanism of activation and function of protein kinase B
Alessi, D. R., & Cohen, P. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80062-2 · Cited by 743 · cited 2×
“activating phosphorylation of residues including Ser-473 at the COOH terminus (17, 18).”
BackgroundMethodMartin, G. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35073094 · Cited by 599
Cited by
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
The Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
“Abrogating Src signaling has been shown to restore sensitivity to gemcitabine in tumor and tissue transplants cell lines derived from the pancreas [45,46,88].”
BackgroundCD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
Hong, S. P., Wen, J., Bang, S., Park, S., & Song, S. Y. (2009) · International Journal of Cancer · doi:10.1002/ijc.24573 · Cited by 290
“Gemcitabine-resistant pancreatic cancer cells were established by escalating doses of gemcitabine serially in HPAC and CFPAC1 cells.(9) Initially, cells were cultured for 72 hr with IC50 of gemcitabine with a defined drug-free interval.”
MethodDasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
Adjei, A. A., & Hidalgo, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.648 · Cited by 238
Metadata
- Authors
- Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- Clinical Cancer Research
- Published
- 2004-04-01
- Volume
- 10
- Issue
- 7
- Pages
- 2307-2318
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2117844134
- Cited by
- 192
- References
- 60
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 11 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 9 · 2018: 2 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 12 · 2013: 6 · 2012: 16
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- Src kinase, gemcitabine resistance, pancreatic ductal adenocarcinoma, PP2, RRM2, ribonucleotide reductase, E2F1, caspase-dependent apoptosis, chemosensitization, combination chemotherapy, metastasis, Src phosphorylation, tumor xenografts, metastatic pancreatic cancer
- MeSH terms
- Gemcitabine, Adenocarcinoma, Animals, Antimetabolites, Antineoplastic, Antineoplastic Agents, Cell Division, Cell Nucleus, Deoxycytidine, DNA-Binding Proteins, Dose-Response Relationship, Drug, Genes, Dominant, Humans, Mice, Nude, Neoplasm Metastasis, Neoplasm Transplantation, Pancreatic Neoplasms, Phosphorylation, Pyrimidines, Ribonucleoside Diphosphate Reductase, Transcription Factors, Tyrosine, Blotting, Northern, Blotting, Western, Apoptosis, Cell Cycle Proteins, Drug Resistance, Neoplasm, src-Family Kinases, Inhibitory Concentration 50, Caspases, Cell Line, Tumor, E2F Transcription Factors, E2F1 Transcription Factor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-1183-3
- The paper
- Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004). Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-1183-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.